<?xml version="1.0" encoding="UTF-8"?>
<p id="Par32">Given that S1P is crucially involved in vascular barrier function, coagulation, vascular homeostasis, angiogenesis, and atherosclerosis, Fingolimod has been reported to induce bradyarrhythmia, atrioventricular block, and blood pressure through increasing the vascular tone [
 <xref ref-type="bibr" rid="CR81">81</xref>, 
 <xref ref-type="bibr" rid="CR82">82</xref>]. Regarding fingolimod-induced intracellular calcium release and its consequent contractile effects on smooth muscle cells, it may cause retinal arterial vasospasm and retinal vein occlusion [
 <xref ref-type="bibr" rid="CR76">76</xref>, 
 <xref ref-type="bibr" rid="CR81">81</xref>]. Conversely, upon its atheroprotective effects, fingolimod diminishes atherosclerosis plaque volume and macrophage and collagen content in vivo [
 <xref ref-type="bibr" rid="CR83">83</xref>]. In another perspective, through S1P cascade to p-21 activated kinase (Pak1), a pivotal regulator of channel activity and contractility, fingolimod resists load stress-induced murine hypertrophic remodeling without deterioration of cardiac function [
 <xref ref-type="bibr" rid="CR83">83</xref>].
</p>
